A biomaterial platform for T cell-specific gene delivery
Acta Biomaterialia · 2024-03 · 177 · 157-164
DOI: 10.1016/j.actbio.2024.02.013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2024-03. Verfasst von Sharda Pandit und 3 weiteren Autor:innen. Beteiligte Einrichtung: Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, USA; Compar…. Hauptthemen laut MEDLINE: T-Lymphocytes, Leukocytes, Mononuclear. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Efficient T cell engineering is central to the success of CAR T cell therapy but involves multiple time-consuming manipulations, including T cell isolation, activation, and transduction. These steps add complexity and delay CAR T cell manufacturing, which takes a mean time of 4 weeks. To streamline T cell engineering, we strategically combine two critical engineering solutions - T cell-specific lentiviral vectors and macroporous scaffolds - that enable T cell activation and transduction in a simple, single step. The T cell-specific lentiviral vectors (referred to as STAT virus) target T cells through the display of an anti-CD3 antibody and the CD80 extracellular domain on their surface and provide robust T cell activation. Biocompatible macroporous scaffolds (referred to as Drydux) mediate robust transduction by providing effective interaction between naïve T cells and viral vectors. We show that when unstimulated peripheral blood mononuclear cells (PBMCs) are seeded together with STAT lentivirus on Drydux scaffolds, T cells are activated, selectively transduced, and reprogrammed in a single step. Further, we show that the Drydux platform seeded with PBMCs and STAT lentivirus generates tumor-specific functional CAR T cells. This potent combination of engineered lentivirus and biomaterial scaffold holds promise for an effective, simple, and safe avenue for in vitro and in vivo T cell engineering. STATEMENT OF SIGNIFICANCE: Manufacturing T cell therapies involves lengthy and labor-intensive steps, including T cell selection, activation, and transduction. These steps add complexity to current CAR T cell manufacturing protocols and limit widespread patient access to this revolutionary therapy. In this work, we demonstrate the combination of engineered virus and biomaterial platform that, together, enables selective T cell activation and transduction in a single step, eliminating multistep T cell engineering protocols and significantly simplifying the manufacturing process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, USA; Comparative Medicine Institute, North Carolina State University, Raleigh, NC…
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA; Program in Immunology, Harvard Medical School, Boston, MA, USA.
- Koch Institute for Integrative Cancer Research, Cambridge, MA, USA; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA…
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- North Carolina State University
- Bill and Melinda Gates Foundation
- Office of Sex Offender Sentencing, Monitoring, Apprehending, Registering, and Tracking
Zitieren
APA
Pandit, S., Smith, B. E., Birnbaum, M. E., & Brudno, Y. (2024). A biomaterial platform for T cell-specific gene delivery. Acta Biomaterialia, 177, 157-164. https://doi.org/10.1016/j.actbio.2024.02.013
Vancouver
Pandit S, Smith BE, Birnbaum ME, Brudno Y. A biomaterial platform for T cell-specific gene delivery. Acta Biomaterialia. 2024;177:157-164. doi:10.1016/j.actbio.2024.02.013
BibTeX
@article{Pandit2024,
author = {Pandit, Sharda and Smith, Blake E and Birnbaum, Michael E and Brudno, Yevgeny},
title = {A biomaterial platform for T cell-specific gene delivery},
journal = {Acta Biomaterialia},
year = {2024},
volume = {177},
pages = {157--164},
doi = {10.1016/j.actbio.2024.02.013}
}
EUVIMED